Expression of Frat1 correlates with expression of β-catenin and is associated with a poor clinical outcome in human SCC and AC

Tumor Biology

Volumn 33, Issue 5, 2012, Pages 1437-1444

  Zhang, Yong ^a   Han, Yang ^a   Zheng, Rui ^a   Yu, Juan Han ^a   Miao, Yuan ^a   Wang, Liang ^a   Wang, En Hua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Frat1; NSCLC; Wnt pathway; Catenin

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; FREQUENTLY REARRANGED IN ADVANCED T CELL LYMPHOMAS 1 PROTEIN; ONCOPROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG SURGERY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; UPREGULATION;

EID: 84868156567     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0394-3     Document Type: Article

References (21)

1. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell. 2000;103:311-20.
2. Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol. 2003;129:199-221.
3. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 2004;303:1483-7.
4. Kimelman D, Xu W. Beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene. 2006;25:7482-91.
5. Clements WM, Wang J, Sarnaik A, Kim OJ, MacDonald J, Fenoglio-Preiser C, Groden J, Lowy AM. Beta-catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res. 2002;62:3503-6.
6. Hedgepeth CM, Deardorff MA, Rankin K, Klein PS. Regulation of glycogen synthase kinase 3beta and downstream Wnt signaling by axin. Mol Cell Biol. 1999;19:7147-57.
7. Thomas GM, Frame S, Goedert M, Nathke I, Polakis P, Cohen P. A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and beta-catenin. FEBS Lett. 1999;458:247-51.
8. Dajani R, Fraser E, Roe SM, Yeo M, Good VM, Thompson V, Dale TC, Pearl LH. Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. EMBO J. 2003;22:494-501.
9. Haeseleer F, Pollet JF, Bollen A, Jacobs P. Molecular cloning and sequencing of the attachment site and integrase gene of the temperate mycobacteriophage FRAT1. Nucleic Acids Res. 1992;20:1420.
10. Wang Y, Liu S, Zhu H, Zhang W, Zhang G, Zhou X, Zhou C, Quan L, Bai J, Xue L, Lu N, Xu N. Frat1 overexpression leads to aberrant activation of beta-catenin/TCF pathway in esophageal squamous cell carcinoma. Int J Cancer. 2008;123:561-8.
11. Wang Y, Hewitt SM, Liu S, Zhou X, Zhu H, Zhou C, Zhang G, Quan L, Bai J, Xu N. Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours. Br J Cancer. 2006;94:686-91.
12. Guo G, Mao X, Wang P, Liu B, Zhang X, Jiang X, Zhong C, Huo J, Jin J, Zhuo Y. The expression profile of FRAT1 in human gliomas. Brain Res. 2010;1320:152-8.
13. Guo G, Liu B, Zhong C, Zhang X, Mao X, Wang P, Jiang X, Huo J, Jin J, Liu X, Chen X. FRAT1 expression and its correlation with pathologic grade, proliferation, and apoptosis in human astrocytomas. Med Oncol. 2011;28:1-6.
14. Zhang Y, Yu JH, Lin XY, Miao Y, Han Y, Fan CF, Dong XJ, Dai SD, Wang EH. Overexpression of Frat1 correlates with malignant phenotype and advanced stage in human non-small cell lung cancer. Virchows Arch. 2011;459:255-63.
15. Jonkers J, Korswagen HC, Acton D, Breuer M, Berns A. Activation of a novel proto-oncogene, Frat1, contributes to progression of mouse T-cell lymphomas. EMBO J. 1997;16:441-50.
16. Freemantle SJ, Portland HB, Ewings K, Dmitrovsky F, DiPetrillo K, Spinella MJ, Dmitrovsky E. Characterization and tissue-specific expression of human GSK-3-binding proteins Frat1 and Frat2. Gene. 2002;291:17-27.
17. Kirikoshi H, Katoh M. Expression of WNT7A in human normal tissues and cancer, and regulation of WNT7A and WNT7B in human cancer. Int J Oncol. 2002;21:895-900.
18. Lim SC, Lee MS. Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer. Oncol Rep. 2002;9:915-28.
19. Hay E, Faucheu C, Suc-Royer I, Touitou R, Stiot V, Vayssiere B, Baron R, Roman-Roman S, Rawadi G. Interaction between LRP5 and Frat1 mediates the activation of the Wnt canonical pathway. J Biol Chem. 2005;280:13616-23.
20. Hino S, Michiue T, Asashima M, Kikuchi A. Casein kinase I epsilon enhances the binding of Dvl-1 to Frat-1 and is essential for Wnt-3a-induced accumulation of beta-catenin. J Biol Chem. 2003;278:14066-73.
21. van Amerongen R, Nawijn MC, Lambooij JP, Proost N, Jonkers J, Berns A. Frat oncoproteins act at the crossroad of canonical and noncanonical Wnt-signaling pathways. Oncogene. 2010;29:93-104.